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Telomerase activation in nasopharyngeal carcinomas
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Summary Nasopharyngeal carcinomas (NPC) are common in Hong Kong and southern China but rare in Western countries. Telomerase
activation is common in human cancers but has not been reported previously in NPC. Telomerase activation in NPC was determined using
the sensitive TRAP (telomerase rapid amplification protocol) assay in 45 nasopharyngeal biopsies (36 NPC, nine normal nasopharyngeal
mucosae) in four xenografted NPC tumours established in nude mice and in five in vitro NPC cell lines. Telomerase activation is common in
NPC and can be detected at high frequencies (85% in primary tumours and 100% in recurrent tumours). The frequency of telomerase
activation was lowest in NPC biopsies without lymph node involvement (60%) compared with those with positive lymph node involvement
(100%), and the difference is statistically significant (P < 0.05; Fisher exact test). All the xenografted NPC tumours and in vitro NPC cell lines
were strongly positive for telomerase activity. Our results suggest that telomerase activation is common in NPC and it may be useful as a
diagnostic marker in the detection of tumour cells in nasopharyngeal biopsies. The high frequency of telomerase activation in stage I NPC
(80% positive) suggests that it is an early event in tumour progression.
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Nasopharyngeal carcinoma (NPC) is a common cancer in Hong
Kong and the southem China region. The incidence of NPC in
Chinese living in Hong Kong, SouthChina, Taiwan and Singapore
is 25 times higher than Caucasians living in the European and
American continents (Muir et al, 1987). The molecular basis ofthe
pathogenesis of NPC is poorly understood. In contrast to many
other human cancers, mutations of the p53 and Rb genes are
uncommon events in NPC (Spruck et al, 1992; Sun et al, 1993).
Homozygous deletion of chromosome 9p is common in NPC
(Huang et al, 1994) and involves thepi6 gene (Lo et al, 1995). In
addition, loss of heterozygosity involving chromosome 3p is a
common event in NPC (Huang et al, 1991). We have recently
mapped a common region of deletion at chromosome 3pl3-14.3
in NPC (Lo et al, 1994), involving the locus of a recently cloned
tumour-suppressor gene (FHIT) (Ohta et al, 1996). Aberrant
transcripts of the FHIT gene were also detected in NPC cell lines
(Kastury et al, 1996).
The incidence of NPC starts to increase at around age 20-24
years, peaks at age 40-60 years and then gradually decreases
(Huang et al, 1991). NPC responds well to radiation therapy,
which is the major treatment modality atpresent (Tsao et al, 1991).
NPC diagnosed at its early stage is associated with better prog-
nosis. A marker capable ofdetecting the presence oftumour cells
in NPC biopsies wouldbeparticularly useful in the early diagnosis
of NPC. Such a marker would also be useful in the detection of
tumour cells in residual tumour after radiation treatment.
Telomerase is a ribonucleoprotein enzyme that maintains the
telomeric length at chromosomal ends with simple repetitive
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sequences (Avilion etal, 1996). Itcompensates for the end replica-
tion problem associated with cell division and allows cells to
proliferate indefinitely (Kim et al, 1994). Telomerase activation is
common in malignant transformation (Chadeneau et al, 1995).
Prognostic value of telomerase activation has been implicated in
some human cancers, such as neuroblastoma (Hiyama et al,
1995a) and gastric cancers (Hiyama et al, 1995b). Telomerase
activation in NPC has not been previously investigated, and its
usefulness in clinical application is completely unknown. In this
study, we have examined telomerase activity in biopsied NPC
tissues obtained from primary and recurrent nasopharyngeal
cancers and have evaluated its potential application as a malignant
marker for the detection oftumour cells in NPC biopsies.
MATERIALS AND METHODS
NPC biopsies, cell lines and xenografted NPC
Forty-five nasopharyngeal biopsies (36 tumours and nine non-
neoplastic nasopharyngeal tissues) were obtained for this study.
Informed consents for the use of clinical materials for telomerase
study were obtained from patients. The NPC biopsies used in this
study were examined by cryosectioning to confirm the absence or
presence of tumour cells. The biopsies were then extracted and
assayed fortelomerase activity. All the NPC biopsies, except those
from recurrent cancers, were collected from patients before
chemotherapy or radiotherapy. Nine non-cancerous nasopharyn-
geal mucosae were obtained as controls and they were obtained
either from patients undergoing radical head and neck surgery or
from patients with suspected NPC lesions but laterconfirmed to be
negative for NPC. All the non-neoplastic nasopharyngeal tissues
were confirmed histologically to be free oftumour cells.
The establishment of the xenografted NPC tumours, 2117 and
666, and the in vitro cell lines, HK1, CNE1, CNE2 and 666, has
been previously published (Gu et al, 1983; Huang et al, 1980,
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Figure 1 Telomerase activity in nasopharyngeal carcinomas. Tissue extracts were assayed for telomerase activity at two concentrations, 6 ,ug and 0.6gg,
per reaction. NP, normal nasopharyngeal mucosa; NPC, nasopharyngeal carcinoma; Met 1, Met 2 and 666 are xenografted tumours established from NPC
biopsies. +, Telomerase assay conducted in the presence of RNAase (0.5 gg per reaction) to confirm the specifity of the telomerase assay. -, Telomerase assay
conducted without RNAase. Note that the PCR-amplified products of telomerase are longer in assays using lower concentrations of tissue extract, indicating the
presence of inhibitors in the extract
1989). One NPC cell line (391) and the two NPC xenografts
(MET1 and MET2) were obtained from the Microbiology
Department, University ofHong Kong.
Clinical staging
The clinical staging of the nasopharyngeal carcinomas was
according to the TNM staging system (reviewed by Wei and
Sham, 1994). Details of the classification are as follows: stage I,
tumour confined to the nasopharyngeal mucosa (TlN0); stage II,
tumour extended to nasal fossa, oropharynx oradjacent muscles or
nerves below the base ofskull (T2) and/orNI involvement (TIN1,
T2NO and T2N1); stage III, tumour extended beyond T2 limits or
bone involvement (T3) and/or N2 involvement (TIN2, T2N2,
T3NO and T3N1); and stage IV, N3 irrespective of the primary
tumour (Tl, N3, T2N3, T3N3).
EBV serology
The titres of serum immunoglobulin A against the viral capsid
antigen (IgA/VCA) ofEpstein-Barr virus (EBV) of NPC patients
were determined by indirect immunofluorescence techniques. The
titre of 1:10 was considered as seropositive for EBV.
TRAP assay
Telomerase activity was determined using the TRAP assay
according to previously published procedures (Piatyszek et al,
1995). All precautions for RNAase contamination were observed.
Tumour tissues or cell pellets were homogenized by a motorized
disposable pestle (VWR Scientific, Sugar Land, TX, USA) in
cold CHAPS buffer (10 mm Tris-HCI pH 7.5, 1 mm magnesium
chloride, 1 mM EGTA, 0.1 mm phenylmethylsulphonyl fluoride,
5 mM ,-mercaptomethanol, 0.5% w/v CHAPS (3-[(3-cholamido-
propyl)-dimethyl-ammonio]-l-propanesulphonate), 10% glyc-
erol). The homogenate was kept on ice for 30 min and spun at
12 000g for 30 min at 4°C. The supernatant was carefully
removed and the protein concentration was determined by
Coomassie protein assay reagent (Pierce Chemical, Rockford, IL,
USA). To dilute out the effect of telomerase inhibitors that
may be present in the sample extract, telomerase activity from
each specimen was assayed at two concentrations (1 x, 10 x
dilutions). All the samples that were negative for telomerase
were mixed with positive telomerase control and reassayed for
telomerase activity to confirm the absence oftelomerase inhibitor
in the sample extract. Assay tubes were prepared by sequestering
0.1 gg of CX primer (5'-CCCTFACCCTTACCCTTACCCTAA-
3') under a wax barrier (Ampli-wax; Perkin-Elmer, Foster City,
CA, USA). Each tumour extract was assayed above the wax
barrier in 50gl ofreaction mixture containing 5 ,l of 10 x TRAP
buffer (200 mm Tris-HCl pH 8.3, 15 mm magnesium chloride;
630 mm potassium chloride; 0.05% Tween 20; 10 mm EGTA;
1 mg ml-' bovine serum albumin), 1 gl of 2.5 mM dNTPs, 1 gl of
TS primer (5'-AATCCGTCGAGCAGAGTT-3'; 0.1 jig jl-),
0.4 pl (2 U) Taq polymerase (Boehringer Mannheim), 40.2gl of
DEPC (diethyl pyrocarbonate) water, 0.4,1 of [a-32P]dCTP
(3000 Ci mmol-', Amersham) and 2gl oftelomerase extract (0.6-
6.0 jig of protein). The tube was then incubated at room
temperature for 20 min before polymerase chain reaction (PCR)
amplification (25 cycles of94°C/30 s, 50°C/30 s, 72°C/30 s). Four
microlitres of loading dye containing bromophenol blue was then
added. The products were run on 15% non-denaturing PAGE gel
in 0.6 x TBE. The gel was then dried and the TRAP products were
visualized by autoradiography. RNAase control was set up with
each tumour extract by preincubating with 0.5 jg ofDNAase-free
RNAase at room temperature for 15 min.
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Table 1 Telomerase activities in biopsied nasopharyngeal carcinomas
Case no. Sex Age Clinical Ho's Telomerase Presence of EBV serology Keratin
(years) staginga stagingb activity tumour cells (IgA to VCA titres)
Normal nasopharyngeal mucosa
HKNP3 M
HKNP8 M
HKNP9 F
HKNP17 F
HKNP25 M
HKNP26 M
HKNP32 M
HKNP39 F
HKNP46 F
Primarynasopharyngeal carcinomas
HKNPC5 M
HKNPC10 F
HKNPC18 F
HKNPC22 M
HKNPC28 M
HKNPC24 F
HKNPC30 F
HKNPC4 M
HKNPC20 M
HKNPC54 M
HKNPC44 M
HKNPC19 M
HKNPC21 F
HKNPC29 F
HKNPC31 M
HKNPC6 M
HKNPC9 M
HKNPC40 F
HKNPC42 M
HKNPC45 M
HKNPC16 M
HKNPC23 F
HKNPC26 M
HKNPC27 M
HKNPC35 M
HKNPC39 F
HKNPC53 M
38
29
44
17
38
41
44
31
67
49
42
46
57
48
47
46
37
53
60
70
68
67
52
49
46
63
20
67
45
41
37
41
73
26
31
52
I1
I1
I1
I1
I1
11
11
11
11
11
111
111
111
111
111
IV
IV
IV
IV
IV
IV
IV
Ti NO
Ti NO
Ti NO
Ti NO
Ti NO
T1Nl
Ti NI
T2NO
T2NO
T2NO
T2NO
T2N1
T2N1
T2N1
T2N1
T2N2
Ti N2
Ti N2
T2N2
T3NO
T2N3
T3N2
T3N3
T3N1
T3N1
Ti N3
Ti N3
Recurrent cancers (neck node metastasis)
HKNPC7A M 34
HKNPC2 M 52
HKNPC3 M 39
HKNPC7 M 44
HKNPC13 M 65
HKNPC14 M 62
HKNPC34 F 26
HKNPC49 M 62
HKNPC51 M 65
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
aWei and Sham (1994); bWei (1984); EBV serology, diagnostic titres: 1:10; NA, not available.
Western analysis of cytokeratin in NPC biopsies RESULTS
Apart from histological confirmation of tumour cells in the NPC
biopsies, we have also examined the presence of keratin in these
biopsies to confirm the presence of epithelial cells (Tsao et al,
1995). The detection of keratin was particularly useful in estab-
lishing the presence of epithelial cells in normal nasopharyngeal
biopsies, which were often small in size (1 mm3). The cytokeratin
extract was solubilized in loading buffer, resolved by 12% SDS-
PAGE and transferred to PVDF membrane for immunodetection
using AEI and AE3 antibodies (Zymed Laboratories, South San
Francisco, CA, USA) against cytokeratins.
Telomerase activity was present in 32 out of 36 NPC specimens
(89%) and in none out of nine non-neoplastic nasopharyngeal
tissues (0%) (Figure 1).
The telomerase activities of all the 36 NPC biopsies are shown
in Table 1. Positive telomerase activity was detected in 23 out of
27 biopsies (85%) obtained from primary NPC and in nine out of
nine biopsies ofrecurrent NPC (100%). Telomerase activation was
common in all stages of NPC: 80% in stage I (four out of five);
70% in stage II (seven out of ten); 100% in stage III (five out of
five) and 100% in stage IV (seven out of seven). There was,
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Table 2 Telomerase activity in established cell lines of nasopharyngeal
carcinoma
Nasopharyngeal carcinomas Telomerase activity
Xenografted tumours
2117 +
666 +
MET1 +
MET2 +
In vitro celllines
HK1 +
666 +
CNE1 +
CNE2 +
391 +
Normal nasopharyngeal epithelial cells
HKNP1
HK1 CNE1 CNE2 666 SiHa
+ _ + _ + - + _ + -
Figure 2 Telomerase activity in established carcinoma cell lines HK1,
CNE1, CNE2 and 666 are established nasopharyngeal carcinoma cell lines.
SiHa is an established cell line of cervical carcinoma. +, Telomerase assay
conducted in the presence of RNAase inhibition (0.5gig per reaction).
-, Telomerase assay conducted in the absence of RNAase. Tissue extract
was used at a protein concentration of 6 ig per reaction
however, no statistical significance observed between biopsies
from early stages (stage I and LI) and advanced stages (stage III
and IV) (P> 0.05; Fisher exact test) ofNPC. However, telomerase
activation in NPC biopsies with negative lymph node involvement
appeared to be lower (six out often cases, 60%) than biopsies with
positive lymph node involvement (17 out of 17 cases, 100%). The
difference was statistically significant (P < 0.05, Fisher exact test).
The status of positive and negative lymph node involvement was
confirmed by computerized tomography (CT) and clinical exami-
nation. All the telomerase activities detected were sensitive to
RNAase inactivation, which confirmned the specificity ofthe assay.
Activation of telomerase was common in established cell lines
of NPC (Table 2). All established NPC cell lines examined were
positive for telomerase activity. These included four xenografted
NPC lines (2117, 666, METI, MET2) (Figure 1) established in
nude mice and four in vitro NPC cell lines (CNEI, CNE2, HKI,
391, 666) (Figure 2).
DISCUSSION
This is the first report oftelomerase activation in NPC. In line with
observations in other human malignancies (Kim et al, 1994;
Chadeneau et al, 1995), telomerase activation is also a common
event in NPC. Telomerase activity can be detected at high
frequency (89%) in NPC biopsies and in all NPC cell lines exam-
ined. Non-neoplastic nasopharyngeal mucosae were negative for
telomerase activity. This is in agreement with the observation that
telomerase activation is closely associated with malignancies but
not with hyperplasia or benign tumours in other human cancers
(Chadeneau et al, 1995; Tahara et al, 1995; Hiyama et al, 1996;
Sommerfeld et al, 1996).
The association of telomerase with cell immortalization has
been demonstrated in several cell systems, including EBV-immor-
talized human lymphocytes (Counter et al, 1994). It was shown
that telomerase activation was not detected in the early phase
of proliferation of B-lymphocytes after infection with EBV.
Telomerase activity was detected only in the immortalized B-cell
clones at the later stage of EBV immortalization. This unique
property of telomerase distinguishes it from other proliferative
markers, such as PCNA and Ki67, which are closely associated
with proliferation. In this study, we only detected telomerase acti-
vation in NPC tissues but not in non-neoplastic nasopharyngeal
biopsies. This is in line with the general observation that telom-
erase is detected in immortalized and cancer cells but not in mortal
somatic cells. In NPC, telomerase activation was observed in all
stages of diseases, suggesting that it is an early event in tumour
progression. A higher frequency of telomerase activation was
observed in advanced NPC compared with early diseases,
however the difference is not statistically significant (P> 0.5). The
sample size in this study may be small for the observation to be
conclusive. There were four histologically confirmed NPC biop-
sies (all from early stages) with negative telomerase activity. The
clinical significance of these telomerase-negative NPCs is not
fully understood at this stage; the clinical history of these telom-
erase-negative NPC patients will be followed closely to examine
any influence on survival or recurrence of the disease. Another
observation is that telomerase activation appears to be more
frequent in NPC biopsies with positive lymph node metastasis
(100% positive rate) than those without lymph node involvement
(60%) (P < 0.05, Fisher exact test), suggesting a positive associa-
tion oftelomerase activity with tumour progression. Other clinical
features examined included tumour differentiation and serological
EBV markers, but no obvious relationship with telomerase activa-
tion has been observed (Table 1).
In view ofthe high frequency of telomerase activation in NPC,
the detection of telomerase activity alone may have limited prog-
nostic value for NPC patients. The prognostic value ofthe level of
telomerase activation in NPC remains to be determined. However,
the high frequency of telomerase activation in NPC biopsies and
its close association with tumour cells suggests that it may be
useful as a malignant marker for the detection of tumour cells in
NPC biopsies. Hence, the telomerase activity may complement the
existing methods used for the diagnosis of NPC, such as sero-
logical markers (e.g. IgA/EBV, IgA/EA) and the PCR method for
EBV. In support ofthis, we were able to detect telomerase activity
in two NPC biopsies (HKNPC 18 and 44) that were seronegative
for EBV VCA. As EBV is present in both NPC cells and lympho-
cytes in biopsies, the use of the PCR method alone will not give
conclusive evidence for the presence oftumour cells in NPC biop-
sies. The telomerase assay has the advantage overthe PCR method
in detecting not only EBV-positive cells but also immortalized
tumour cells. The detection of high telomerase activity in naso-
pharyngeal biopsies may warrant further examinations, including
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repeated biopsies from the patients and careful monitoring of
serological markers for NPC. Another potential application of the
telomerase assay may be in the detection of submicroscopic
tumour foci or premalignant but immortal lesions that may escape
histopathological examination.
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